Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 4/2007

01-12-2007 | Erratum

Normal fasting plasma glucose levels and type 2 diabetes: the high-risk and population strategy for occupational health promotion (HIPOP-OHP) study

Authors: Y. Hayashino, S. Fukuhara, Y. Suzukamo, T. Okamura, T. Tanaka, H. Ueshima

Published in: Acta Diabetologica | Issue 4/2007

Login to get access

Excerpt

The original version of this article unfortunately contained a mistake. The title of the article was incorrectly given. The correct title is as given below. …
Metadata
Title
Normal fasting plasma glucose levels and type 2 diabetes: the high-risk and population strategy for occupational health promotion (HIPOP-OHP) study
Authors
Y. Hayashino
S. Fukuhara
Y. Suzukamo
T. Okamura
T. Tanaka
H. Ueshima
Publication date
01-12-2007
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 4/2007
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-007-0021-8

Other articles of this Issue 4/2007

Acta Diabetologica 4/2007 Go to the issue

Original Article

Clinical and genetic features of childhood-onset Type 2 diabetes in Japan

Original Article

Occurrence of diabetes mellitus in spontaneous intracerebral hemorrhage

Original Article

Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients

Original Article

Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats

Original Article

Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study

Original Article

Effect of dehydroepiandrosterone on insulin sensitivity in Otsuka Long-Evans Tokushima-fatty rats
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits